Citius Pharmaceuticals
(NASDAQ) CTXR
Citius Pharmaceuticals Financials at a Glance
Market Cap
$17.24M
Revenue (TTM)
$3.94M
Net Income (TTM)
$35.89M
EPS (TTM)
$-2.89
P/E Ratio
-0.27
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Price
$0.77
Volume
393,560.688
Open
$0.78
Price
$0.77
Volume
393,560.688
Open
$0.78
Previous Close
$0.77
Daily Range
$0.75 - $0.80
52-Week Range
$0.63 - $2.48
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Price
$0.77
Volume
393,560.688
Open
$0.78
Previous Close
$0.77
Daily Range
$0.75 - $0.80
52-Week Range
$0.63 - $2.48
CTXR News
CTXR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Citius Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
23
CEO
Leonard L. Mazur, MBA
Website
www.citiuspharma.comHeadquarters
Cranford, NJ 07016, US
CTXR Financials
Key Financial Metrics (TTM)
Gross Margin
61%
Operating Margin
-10%
Net Income Margin
-9%
Return on Equity
-49%
Return on Capital
-37%
Return on Assets
-26%
Earnings Yield
-3.70%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$17.24M
Shares Outstanding
22.38M
Volume
393.56K
Short Interest
0.00%
Avg. Volume
942.87K
Financials (TTM)
Gross Profit
$214.25K
Operating Income
$38.53M
EBITDA
$38.20M
Operating Cash Flow
$26.55M
Capital Expenditure
$0.00
Free Cash Flow
$26.55M
Cash & ST Invst.
$4.25M
Total Debt
$1.81M
Citius Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.94M
N/A
Gross Profit
$2.58M
+4807.7%
Gross Margin
65.45%
N/A
Market Cap
$17.24M
N/A
Market Cap/Employee
$749.71K
N/A
Employees
23
N/A
Net Income
$8.22M
+15.8%
EBITDA
$8.45M
+15.4%
Quarterly Fundamentals
Net Cash
$5.89M
+557.9%
Accounts Receivable
$4.05M
N/A
Inventory
$22.64M
+57.4%
Long Term Debt
$681.64K
N/A
Short Term Debt
$1.15M
+461.2%
Return on Assets
-25.56%
N/A
Return on Invested Capital
-36.70%
N/A
Free Cash Flow
$13.01M
-175.3%
Operating Cash Flow
$13.01M
-175.3%